Loading provider…
Loading provider…
Neurology Physician in Boston, MA
NPI: 1407977473Primary Practice Location
MASSACHUSETTS GENERAL HOSPITAL
55 Fruit St, Boston, MA
Primary Employer
Massachusetts General Physicians Organization Inc
massgeneral.org
HQ Phone
Get MD PHD Jorg's Phone NumberMobile
Get MD PHD Jorg's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMA State Medical License
MA State Medical License
2008 - 2025

American Board of Psychiatry and Neurology
Neurology
Rochester General Hospital
Residency • Internal Medicine
2004 - 2005
University of Giessen Faculty of Medicine
Medical School
Until 1996
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 88 | 146 |
| 2 | 99223Initial hospital inpatient care, typically 70 minutes per day | 28 | 28 |
| 3 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 27 | 60 |
| 4 | 99214Established patient office or other outpatient visit, 30-39 minutes | 21 | 22 |
| 5 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 21 | 34 |
Pegylated liposomal doxorubicin‐efficacy in patients with recurrent high‐grade glioma
Authors: Peter Hau, Klaus Fabel, Ulrike Baumgart, Petra Rümmele, Oliver Grauer, Annekatrin Bock, Christopher Dietmaier, Wolfgang Dietmaier, Jörg Dietrich, Christine Dudel, Franz Hübner, R N Tanya Jauch, Elisabeth Drechsel, Ingo Kleiter, Cäcile Wismeth, Anton Zellner, Alexander Brawanski, Andreas Steinbrecher, Jörg Marienhagen, Ulrich Bogdahn
Publication Date: 2004-03
Lead Sponsor: Dana-Farber Cancer Institute
Intervention / Treatment: DRUG: Ponatinib
Lead Sponsor: Massachusetts General Hospital
Collaborators: Eli Lilly and Company, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center
Intervention / Treatment: DRUG: pemetrexed